146 related articles for article (PubMed ID: 27272448)
1. Ovarian function after hematopoietic cell transplantation: a descriptive study following the use of GnRH agonists for myeloablative conditioning and observation only for reduced-intensity conditioning.
Phelan R; Mann E; Napurski C; DeFor TE; Petryk A; Miller WP; Wagner JE; Verneris MR; Smith AR
Bone Marrow Transplant; 2016 Oct; 51(10):1369-1375. PubMed ID: 27272448
[TBL] [Abstract][Full Text] [Related]
2. Fertility Potential and Gonadal Function in Survivors of Reduced-Intensity Hematopoietic Stem Cell Transplantation.
Rotz SJ; Hamilton BK; Wei W; Ahmed I; Winston SA; Ballard S; Bernard RJ; Carpenter P; Farhadfar N; Ferraro C; Friend BD; Gloude NJ; Hayashi RJ; Hoyle K; Jenssen K; Koo J; Lee CJ; Mariano L; Nawabit R; Ngwube A; Lalefar N; Phelan R; Perkins L; Rao A; Rayes A; Sandheinrich T; Stafford L; Tomlinson K; Whiteside S; Wiedl C; Myers K
Transplant Cell Ther; 2024 May; 30(5):534.e1-534.e13. PubMed ID: 38342136
[TBL] [Abstract][Full Text] [Related]
3. Phase II study of gonadotropin-releasing hormone analog for ovarian function preservation in hematopoietic stem cell transplantation patients.
Cheng YC; Takagi M; Milbourne A; Champlin RE; Ueno NT
Oncologist; 2012; 17(2):233-8. PubMed ID: 22282904
[TBL] [Abstract][Full Text] [Related]
4. Ovarian function after allogeneic hematopoietic stem cell transplantation in children and young adults given 8-Gy total body irradiation-based reduced-toxicity myeloablative conditioning.
Komori K; Hirabayashi K; Morita D; Hara Y; Kurata T; Saito S; Tanaka M; Yanagisawa R; Sakashita K; Koike K; Nakazawa Y
Pediatr Transplant; 2019 May; 23(3):e13372. PubMed ID: 30714283
[TBL] [Abstract][Full Text] [Related]
5. Gonadal function and fertility after stem cell transplantation in childhood: comparison of a reduced intensity conditioning regimen containing melphalan with a myeloablative regimen containing busulfan.
Panasiuk A; Nussey S; Veys P; Amrolia P; Rao K; Krawczuk-Rybak M; Leiper A
Br J Haematol; 2015 Sep; 170(5):719-26. PubMed ID: 25974284
[TBL] [Abstract][Full Text] [Related]
6. Reduced-Intensity Conditioning Mitigates Risk for Primary Ovarian Insufficiency but Does Not Decrease Risk for Infertility in Pediatric and Young Adult Survivors of Hematopoietic Stem Cell Transplantation.
Bender JD; Oquendo-Del Toro H; Benoit J; Howell JC; Badia P; Davies SM; Grimley MS; Jodele S; Phillips C; Burns K; Marsh R; Nelson A; Wallace G; Dandoy CE; Pate A; Strine AC; Frias O; Breech L; Rose SR; Hoefgen H; Khandelwal P; Myers KC
Transplant Cell Ther; 2023 Feb; 29(2):130.e1-130.e8. PubMed ID: 36323400
[TBL] [Abstract][Full Text] [Related]
7. Similar risks for chronic kidney disease in long-term survivors of myeloablative and reduced-intensity allogeneic hematopoietic cell transplantation.
Al-Hazzouri A; Cao Q; Burns LJ; Weisdorf DJ; Majhail NS
Biol Blood Marrow Transplant; 2008 Jun; 14(6):658-63. PubMed ID: 18489991
[TBL] [Abstract][Full Text] [Related]
8. Comparative outcome of reduced intensity and myeloablative conditioning regimen in HLA identical sibling allogeneic hematopoietic stem cell transplantation for acute leukemia patients: a single center experience.
Goker H; Ozdemir E; Uz B; Buyukasik Y; Turgut M; Serefhanoglu S; Aksu S; Sayinalp N; Haznedaroglu IC; Tekin F; Karacan Y; Unal S; Eliacik E; Isik A; Ozcebe OI
Transfus Apher Sci; 2013 Dec; 49(3):590-9. PubMed ID: 23981652
[TBL] [Abstract][Full Text] [Related]
9. Female Reproductive Health Outcomes after Hematopoietic Cell Transplantation for Sickle Cell Disease: Is Reduced Intensity Better Than Myeloablative Conditioning?
Meacham LR; George S; Veludhandi A; Pruett MC; Haight AE; Arnold SD; Elchuri S; Stenger E; Krishnamurti L
Transplant Cell Ther; 2023 Aug; 29(8):531.e1-531.e4. PubMed ID: 37169288
[TBL] [Abstract][Full Text] [Related]
10. Assessment of the ovarian reserve with anti-Müllerian hormone in women who underwent allogeneic hematopoietic stem cell transplantation using reduced-intensity conditioning regimens or myeloablative regimens with ovarian shielding.
Nakano H; Ashizawa M; Akahoshi Y; Ugai T; Wada H; Yamasaki R; Ishihara Y; Kawamura K; Sakamoto K; Sato M; Terasako-Saito K; Kimura S; Kikuchi M; Nakasone H; Kako S; Kanda J; Yamazaki R; Tanihara A; Nishida J; Kanda Y
Int J Hematol; 2016 Jul; 104(1):110-6. PubMed ID: 27084256
[TBL] [Abstract][Full Text] [Related]
11. Similar risks for hypothyroidism after allogeneic hematopoietic cell transplantation using TBI-based myeloablative and reduced-intensity conditioning regimens.
Al-Hazzouri A; Cao Q; Burns LJ; Weisdorf DJ; Majhail NS
Bone Marrow Transplant; 2009 Jun; 43(12):949-51. PubMed ID: 19104492
[TBL] [Abstract][Full Text] [Related]
12. Alloreactivity as therapeutic principle in the treatment of hematologic malignancies. Studies of clinical and immunologic aspects of allogeneic hematopoietic cell transplantation with nonmyeloablative conditioning.
Petersen SL
Dan Med Bull; 2007 May; 54(2):112-39. PubMed ID: 17521527
[TBL] [Abstract][Full Text] [Related]
13. Utilization and Outcomes of Fertility Preservation Techniques in Women Undergoing Allogeneic Hematopoietic Cell Transplant.
Higgins A; Khan Z; Coddington CC; Hashmi SK; Hefazi M; Alkhateeb H; Litzow MR; Hogan WJ; Cathcart-Rake E; Thompson CA; Patnaik MM
Biol Blood Marrow Transplant; 2019 Jun; 25(6):1232-1239. PubMed ID: 30772513
[TBL] [Abstract][Full Text] [Related]
14. A Phase I Study of Reduced-Intensity Conditioning and Allogeneic Stem Cell Transplantation Followed by Dose Escalation of Targeted Consolidation Immunotherapy with Gemtuzumab Ozogamicin in Children and Adolescents with CD33+ Acute Myeloid Leukemia.
Zahler S; Bhatia M; Ricci A; Roy S; Morris E; Harrison L; van de Ven C; Fabricatore S; Wolownik K; Cooney-Qualter E; Baxter-Lowe LA; Luisi P; Militano O; Kletzel M; Cairo MS
Biol Blood Marrow Transplant; 2016 Apr; 22(4):698-704. PubMed ID: 26785332
[TBL] [Abstract][Full Text] [Related]
15. Non-myeloablative conditioning for lower-risk myelodysplastic syndrome with bone marrow blasts less than 5 %-a feasibility study.
Choi EJ; Lee JH; Lee JH; Kim DY; Park HS; Seol M; Lee YS; Kang YA; Jeon M; Lee KH
Ann Hematol; 2016 Jun; 95(7):1151-61. PubMed ID: 27106699
[TBL] [Abstract][Full Text] [Related]
16. High rates of ovarian function preservation after hematopoietic cell transplantation with melphalan-based reduced intensity conditioning for pediatric acute leukemia: an analysis from the Japan Association of Childhood Leukemia Study (JACLS).
Fujino H; Ishida H; Iguchi A; Onuma M; Kato K; Shimizu M; Yasui M; Fujisaki H; Hamamoto K; Washio K; Sakaguchi H; Miyashita E; Osugi Y; Nakagami-Yamaguchi E; Hayakawa A; Sato A; Takahashi Y; Horibe K
Int J Hematol; 2019 May; 109(5):578-583. PubMed ID: 30864117
[TBL] [Abstract][Full Text] [Related]
17. A prospective randomized toxicity study to compare reduced-intensity and myeloablative conditioning in patients with myeloid leukaemia undergoing allogeneic haematopoietic stem cell transplantation.
Ringdén O; Erkers T; Aschan J; Garming-Legert K; Le Blanc K; Hägglund H; Omazic B; Svenberg P; Dahllöf G; Mattsson J; Ljungman P; Remberger M
J Intern Med; 2013 Aug; 274(2):153-62. PubMed ID: 23432209
[TBL] [Abstract][Full Text] [Related]
18. Gonadal function of beta-thalassemics following stem cell transplantation conditioned with myeloablative and reduced intensity regimens.
Poomthavorn P; Chawalitdamrong P; Hongeng S; Mahachoklertwattana P; Pakakasama S; Khlairit P; Chailurkit LO
J Pediatr Endocrinol Metab; 2013; 26(9-10):925-32. PubMed ID: 23729599
[TBL] [Abstract][Full Text] [Related]
19. Impact of reduced-intensity conditioning allogeneic stem cell transplantation on women's fertility.
Assouline E; Crocchiolo R; Prebet T; Broussais F; Coso D; Gamerre M; Vey N; Blaise D; Courbiere B
Clin Lymphoma Myeloma Leuk; 2013 Dec; 13(6):704-10. PubMed ID: 24070823
[TBL] [Abstract][Full Text] [Related]
20. Allogeneic stem cell transplantation for patients with advanced hematological malignancies: comparison of fludarabine-based reduced intensity conditioning versus myeloablative conditioning.
Kim I; Lee KH; Choi Y; Keam B; Koo NH; Yoon SS; Yoo KY; Park S; Kim BK
J Korean Med Sci; 2007 Apr; 22(2):227-34. PubMed ID: 17449929
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
